Sunitinib, a receptor tyrosine kinase (RTK) inhibitor, is the first-line treatment for renal cell carcinoma (RCC) patients, which has potent anti-angiogenic and anti-tumor activities by inhibition of VEGF receptor, PDGF receptor, FMS-like tyrosine kinase 3 (FLT3), and stem cell growth factor receptor. The gene discussed is NTRK1; the disease is renal cell carcinoma.